Your Health, We Care
The most common adverse reactions (≥20% in either study) are thrombocytopenia, hemorrhage, bacterial infection, fatigue, dizziness, diarrhea, and nausea.
from FDA,2023.09
Major Cardiovascular Event Risk with MomelotinibRisk BackgroundMomelotinib belon···【more】
Release date：2026-06-23Recommended：137
Momelotinib: Risk of Decreased Platelet and White Blood Cell CountsMomelotinib m···【more】
Release date：2026-06-22Recommended：161
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
